Verdiperstat is under clinical development by Biohaven and currently in Phase III for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration). According to GlobalData, Phase III drugs for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Verdiperstat LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Verdiperstat (AZD-3241) is under development for the treatment of multiple system atrophy, amyotrophic lateral sclerosis, semantic variant primary progressive aphasia (svPPA) due to TDP-43 pathology. The drug candidate is orally administered and formulated in the form of capsules and tablets. It is a new chemical entity. The drug candidate acts by targeting myeloperoxidase (MPO). It was also under development for the treatment of Parkinson's disease.
Biohaven formerly Biohaven Research, is biopharmaceutical company discovering, developing, and commercializing novel therapies for the treatment of neurological and neuropsychiatric diseases. Biohaven is headquartered in Tortola, British Virgin Islands.
For a complete picture of Verdiperstat’s drug-specific PTSR and LoA scores, buy the report here.